JP2004526711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004526711A5 JP2004526711A5 JP2002565966A JP2002565966A JP2004526711A5 JP 2004526711 A5 JP2004526711 A5 JP 2004526711A5 JP 2002565966 A JP2002565966 A JP 2002565966A JP 2002565966 A JP2002565966 A JP 2002565966A JP 2004526711 A5 JP2004526711 A5 JP 2004526711A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- substituent
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 142
- 125000001424 substituent group Chemical group 0.000 claims 94
- 150000003839 salts Chemical class 0.000 claims 71
- 206010028980 Neoplasm Diseases 0.000 claims 60
- 201000011510 cancer Diseases 0.000 claims 60
- 125000000217 alkyl group Chemical group 0.000 claims 36
- 125000003710 aryl alkyl group Chemical group 0.000 claims 36
- 125000003118 aryl group Chemical group 0.000 claims 36
- 239000003814 drug Substances 0.000 claims 33
- 238000004519 manufacturing process Methods 0.000 claims 33
- 201000004624 Dermatitis Diseases 0.000 claims 30
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 28
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims 27
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 26
- 125000004103 aminoalkyl group Chemical group 0.000 claims 20
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- 125000001118 alkylidene group Chemical group 0.000 claims 18
- 125000004104 aryloxy group Chemical group 0.000 claims 16
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 15
- 201000001320 Atherosclerosis Diseases 0.000 claims 15
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 15
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 15
- 201000003883 Cystic fibrosis Diseases 0.000 claims 15
- 201000005569 Gout Diseases 0.000 claims 15
- 206010019280 Heart failures Diseases 0.000 claims 15
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 15
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 15
- 206010033645 Pancreatitis Diseases 0.000 claims 15
- 201000004681 Psoriasis Diseases 0.000 claims 15
- 206010040070 Septic Shock Diseases 0.000 claims 15
- 206010052779 Transplant rejections Diseases 0.000 claims 15
- 238000002399 angioplasty Methods 0.000 claims 15
- 208000006673 asthma Diseases 0.000 claims 15
- 208000010668 atopic eczema Diseases 0.000 claims 15
- 210000004556 brain Anatomy 0.000 claims 15
- 206010006451 bronchitis Diseases 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 239000003937 drug carrier Substances 0.000 claims 15
- 208000006454 hepatitis Diseases 0.000 claims 15
- 231100000283 hepatitis Toxicity 0.000 claims 15
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 15
- 230000000302 ischemic effect Effects 0.000 claims 15
- 208000032839 leukemia Diseases 0.000 claims 15
- 201000006417 multiple sclerosis Diseases 0.000 claims 15
- 208000010125 myocardial infarction Diseases 0.000 claims 15
- 201000008482 osteoarthritis Diseases 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000037803 restenosis Diseases 0.000 claims 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 15
- 239000007787 solid Substances 0.000 claims 15
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 15
- 239000003981 vehicle Substances 0.000 claims 15
- 210000002216 heart Anatomy 0.000 claims 14
- 210000003734 kidney Anatomy 0.000 claims 14
- 210000004185 liver Anatomy 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 10
- 125000002431 aminoalkoxy group Chemical group 0.000 claims 10
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 10
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 claims 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 10
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 10
- 125000001691 aryl alkyl amino group Chemical group 0.000 claims 9
- 125000001769 aryl amino group Chemical group 0.000 claims 9
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims 9
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 210000000578 peripheral nerve Anatomy 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 3
- -1 cycloalkylalkylamino Chemical group 0.000 claims 3
- 210000005036 nerve Anatomy 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26901301P | 2001-02-15 | 2001-02-15 | |
| US10/071,390 US6987184B2 (en) | 2001-02-15 | 2002-02-07 | Isothiazoloanthrones, isoxazoloanthrones, isoindolanthrones and derivatives thereof as JNK inhibitors and compositions and methods related |
| PCT/US2002/004283 WO2002066450A2 (en) | 2001-02-15 | 2002-02-13 | Anthrone derivatives and their use as ink inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004526711A JP2004526711A (ja) | 2004-09-02 |
| JP2004526711A5 true JP2004526711A5 (https=) | 2005-12-22 |
Family
ID=26752159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002565966A Pending JP2004526711A (ja) | 2001-02-15 | 2002-02-13 | Ｊｎｋ阻害剤としてのイソチアゾロアントロン、イソオキサゾロアントロン、イソインドールアントロン及びそれらの誘導体、並びにそれに関連する組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6987184B2 (https=) |
| EP (1) | EP1363891A2 (https=) |
| JP (1) | JP2004526711A (https=) |
| CA (1) | CA2438312A1 (https=) |
| NZ (1) | NZ528034A (https=) |
| WO (1) | WO2002066450A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE465153T1 (de) | 2002-02-28 | 2010-05-15 | Eisai R&D Man Co Ltd | Neue indazolverbindungen mit kondensiertem ring |
| WO2003075917A1 (en) | 2002-03-08 | 2003-09-18 | Signal Pharmaceuticals, Inc. | Combination therapy for treating, preventing or managing proliferative disorders and cancers |
| JP2005522215A (ja) * | 2002-04-12 | 2005-07-28 | セルジーン・コーポレーション | 幹細胞及び前駆細胞の分化のモジュレーション、アッセイ、並びにそれらの使用 |
| US20040034084A1 (en) * | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| CN1668733A (zh) * | 2002-05-30 | 2005-09-14 | 细胞基因公司 | 利用jnk或mkk抑制剂调节细胞分化并治疗骨髓增生异常和脊髓发育不良综合症的方法 |
| US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| NZ540546A (en) * | 2002-11-18 | 2008-03-28 | Celgene Corp | Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| EP1581205A1 (en) * | 2002-11-18 | 2005-10-05 | Celgene Corporation | Methods of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| AU2003298775B2 (en) * | 2002-11-26 | 2008-07-17 | Anthrogenesis Corporation | Cytotherapeutics, cytotherapeutic units and methods for treatments using them |
| US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| WO2004071283A2 (en) * | 2003-02-13 | 2004-08-26 | Anthrogenesis Corporation | Use of umbilical cord blood to treat individuals having a disease, disorder or condition |
| KR20060124610A (ko) * | 2003-11-06 | 2006-12-05 | 셀진 코포레이션 | 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물 |
| KR20060109979A (ko) * | 2003-12-02 | 2006-10-23 | 셀진 코포레이션 | 혈색소병증 및 빈혈의 치료 및 관리를 위한 방법및 조성물 |
| US20050266391A1 (en) * | 2004-01-15 | 2005-12-01 | Bennett Brydon L | Methods for preserving tissue |
| WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
| JP4219289B2 (ja) * | 2004-03-10 | 2009-02-04 | 独立行政法人科学技術振興機構 | 多環性ケトン化合物及びその製造方法 |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| WO2006090698A1 (ja) * | 2005-02-22 | 2006-08-31 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
| US20060223807A1 (en) * | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| DK1957633T3 (en) | 2005-10-13 | 2014-03-17 | Anthrogenesis Corp | Immunomodulation USING PLACE SPEECH STEM CELLS |
| CA2633980A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
| WO2007093873A1 (en) * | 2006-02-13 | 2007-08-23 | Council Of Scientific And Industrial Research | Bis-pyrr0l0[2,l-c] [1, 4] benzodiazepine- anthraquinone conjugates as antitumour agents and a process for the preparation thereof |
| EP3763376A1 (en) * | 2007-02-12 | 2021-01-13 | Celularity, Inc. | Treatment of inflammatory diseases using placental stem cells |
| US20100239500A1 (en) * | 2007-03-30 | 2010-09-23 | Bixby John L | Substituted triazine compounds for nerve regeneration |
| WO2009111264A2 (en) * | 2008-02-29 | 2009-09-11 | Alseres Pharmaceuticals, Inc. | Systemic purine administration:modulating axonal outgrowth of central nervous system neurons |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2598864B1 (en) * | 2010-07-26 | 2024-06-12 | Parker-Hannifin Corporation | Electrode, analyte sensor and method for preparing an electrode |
| US8969315B2 (en) | 2010-12-31 | 2015-03-03 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
| JP6104896B2 (ja) | 2011-06-01 | 2017-03-29 | アントフロゲネシス コーポレーション | 胎盤幹細胞を使用する疼痛の治療 |
| EP3328819B1 (en) * | 2015-07-28 | 2020-04-01 | Beta Cat Pharmaceuticals, Inc. | Anthracene-9, 10-dione dioxime compounds prodrugs and their uses |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2733976A (en) * | 1956-02-07 | Sulfonateds-acylamino | ||
| GB355597A (en) | 1929-11-12 | 1931-08-27 | Ig Farbenindustrie Ag | Manufacture of carboxylic acid derivatives of the anthraquinone series |
| DE1026315B (de) * | 1954-08-17 | 1958-03-20 | Bayer Ag | Verfahren zur Herstellung von Acylamino-amino-anthrachinonen |
| US3095415A (en) * | 1958-05-30 | 1963-06-25 | Ciba Ltd | Anthraquinone dyestuffs containing a 2-chloro, 4-hydroxy (lower) alkylamino, triazinylamino group |
| DE1164003B (de) * | 1961-08-05 | 1964-02-27 | Bayer Ag | Verfahren zur Herstellung von Anthrachinonfarbstoffen |
| GB960235A (en) * | 1961-08-08 | 1964-06-10 | Ici Ltd | New disperse dyestuffs of the polycyclic ketone series |
| CH428043A (fr) * | 1965-08-16 | 1967-01-15 | Sandoz Ag | Procédé de fabrication de colorants de dispersion isothiazolantroniques |
| CH538527A (de) | 1968-11-07 | 1973-06-30 | Hoechst Ag | Verfahren zur Herstellung von faserreaktiven Farbstoffen |
| DE2200127A1 (de) | 1972-01-03 | 1973-07-12 | Basf Ag | Verfahren zur herstellung von dichlor1,1'-dianthrachinonylen und deren derivaten |
| DE2558813C2 (de) * | 1975-12-27 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Lichtempfindliches Gemisch mit synergistischem Initiatorsystem |
| DE2558812C2 (de) * | 1975-12-27 | 1987-04-30 | Hoechst Ag, 6230 Frankfurt | Photopolymerisierbares Gemisch |
| US4198518A (en) | 1977-09-02 | 1980-04-15 | Ciba-Geigy Corporation | Process for the production of 3-substituted pyrazolanthrones |
| DE2950876A1 (de) * | 1979-12-18 | 1981-06-25 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von triazinylamino-anthrachinonen |
| JPS6028454A (ja) * | 1983-07-27 | 1985-02-13 | Mitsubishi Chem Ind Ltd | アントロン系化合物及び反応性アントロン系染料 |
| JPH0625311B2 (ja) | 1985-07-09 | 1994-04-06 | 住友化学工業株式会社 | 分散型水不溶性染料組成物 |
| JP2001502315A (ja) * | 1996-10-10 | 2001-02-20 | プローブ・インターナショナル | ウイルス感染を処置するための組成物および方法 |
| US6162613A (en) | 1998-02-18 | 2000-12-19 | Vertex Pharmaceuticals, Inc. | Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases |
| DE69900847T2 (de) | 1998-04-17 | 2002-09-12 | Tufts College | Map kinase-inhibitoren zur behandlung von durch tnf-alpha induzierte lipolyse- verursachte krankheiten |
| AU3786899A (en) | 1998-05-04 | 1999-11-23 | Vertex Pharmaceuticals Incorporated | Crystallizable jnk complexes |
| CN1136217C (zh) | 1998-12-17 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 作为jnk蛋白质激酶抑制剂的4-芳基羟吲哚 |
| DE60041763D1 (de) | 1999-04-23 | 2009-04-23 | Vertex Pharma | Inhibitoren von c-jun n-terminal kinasen (jnk) |
| AU5316900A (en) | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
| BR0013551A (pt) | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
| EP1390052A4 (en) | 2001-04-24 | 2008-10-08 | Harvard College | INHIBITION OF JUN KINASE |
-
2002
- 2002-02-07 US US10/071,390 patent/US6987184B2/en not_active Expired - Fee Related
- 2002-02-13 WO PCT/US2002/004283 patent/WO2002066450A2/en not_active Ceased
- 2002-02-13 NZ NZ528034A patent/NZ528034A/en unknown
- 2002-02-13 CA CA002438312A patent/CA2438312A1/en not_active Abandoned
- 2002-02-13 JP JP2002565966A patent/JP2004526711A/ja active Pending
- 2002-02-13 EP EP02720975A patent/EP1363891A2/en not_active Withdrawn
-
2003
- 2003-04-04 US US10/407,107 patent/US20040092562A1/en not_active Abandoned
-
2005
- 2005-06-22 US US11/159,592 patent/US7354947B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004526711A5 (https=) | ||
| JP2003532626A5 (https=) | ||
| RU98123097A (ru) | Карбоксамиды бензофурана и их терапевтическое применение | |
| JP2012522793A5 (https=) | ||
| KR20180118535A (ko) | 아미노피리미딘 유도체 화합물의 염, 이의 결정형 및 이의 제조 방법 | |
| FR2511377A1 (fr) | Nouvelles cephalosporines, et leurs sels | |
| JP2020535165A5 (https=) | ||
| DE2900961A1 (de) | Cephalosporine und verfahren zu deren herstellung | |
| DE2702527A1 (de) | Azetidinon-verbindungen, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von cephalosporinen | |
| DE2415402A1 (de) | Cephalosporansaeurederivate, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen | |
| CN104744493B (zh) | 3‑苯甲酰基‑5,7‑二苯基‑5H‑噻唑并[3,2‑a]嘧啶类衍生物及其应用 | |
| JP2006516984A (ja) | 不水溶性チアゾール誘導体の安定なナノ粒子及び中鎖トリグリセリドのような賦形剤を含む水性分散液 | |
| CA2422703A1 (en) | Process for the preparation of mesylates of piperazine derivatives | |
| CN105658649A (zh) | 1-(哌嗪-1-基)-2-([1,2,4]三唑-1-基)-乙酮衍生物 | |
| CA2389647A1 (en) | Isoxazole derivatives as phosphodiesterase vii inhibitors | |
| CA2520892A1 (en) | Chromenoneindoles | |
| JPS6016969A (ja) | ３−アシルアミノ−２−オキソアゼチジン−１−（β−オキソプロピオン酸） | |
| CH625245A5 (https=) | ||
| CN104844628B (zh) | 2H,6H‑嘧啶并[2,1‑b][1,3]噻嗪类衍生物及其应用 | |
| CA2527587A1 (en) | Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists | |
| JP2014509297A5 (https=) | ||
| EP0335144A1 (de) | Neue 3,4,5-substituierte 4H-1,2,4-Triazole, ihre Herstellung und Verwendung | |
| CH642969A5 (de) | 7-trimethylsilyloxycarbonylamino-cephalosporinverbindungen und ihre verwendung zur herstellung von cephalosporinen. | |
| JPH05112574A (ja) | 新規なセフアロスポリン化合物およびその製法 | |
| CA2540109A1 (en) | Method for stabilization of diarylvinylene compounds |